AU2010279678B2 - Composition and methods of treating viral infections and viral induced tumors - Google Patents

Composition and methods of treating viral infections and viral induced tumors Download PDF

Info

Publication number
AU2010279678B2
AU2010279678B2 AU2010279678A AU2010279678A AU2010279678B2 AU 2010279678 B2 AU2010279678 B2 AU 2010279678B2 AU 2010279678 A AU2010279678 A AU 2010279678A AU 2010279678 A AU2010279678 A AU 2010279678A AU 2010279678 B2 AU2010279678 B2 AU 2010279678B2
Authority
AU
Australia
Prior art keywords
cells
virus
compound
cmx001
jcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010279678A
Other languages
English (en)
Other versions
AU2010279678A1 (en
Inventor
Ernest R. Lanier
George R. Painter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Biodefense Operations Lansing Inc
Original Assignee
Emergent Biodefense Operations Lansing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Biodefense Operations Lansing Inc filed Critical Emergent Biodefense Operations Lansing Inc
Publication of AU2010279678A1 publication Critical patent/AU2010279678A1/en
Application granted granted Critical
Publication of AU2010279678B2 publication Critical patent/AU2010279678B2/en
Priority to AU2015264949A priority Critical patent/AU2015264949A1/en
Assigned to EMERGENT BIODEFENCE OPERATIONS LANSING LLC reassignment EMERGENT BIODEFENCE OPERATIONS LANSING LLC Request for Assignment Assignors: CHIMERIX, INC.
Assigned to EMERGENT BIODEFENSE OPERATIONS LANSING LLC reassignment EMERGENT BIODEFENSE OPERATIONS LANSING LLC Request to Amend Deed and Register Assignors: EMERGENT BIODEFENCE OPERATIONS LANSING LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010279678A 2009-08-03 2010-08-02 Composition and methods of treating viral infections and viral induced tumors Active AU2010279678B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015264949A AU2015264949A1 (en) 2009-08-03 2015-12-07 Composition and methods of treating viral infections and viral induced tumors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23093109P 2009-08-03 2009-08-03
US61/230,931 2009-08-03
PCT/US2010/044093 WO2011017253A1 (en) 2009-08-03 2010-08-02 Composition and methods of treating viral infections and viral induced tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015264949A Division AU2015264949A1 (en) 2009-08-03 2015-12-07 Composition and methods of treating viral infections and viral induced tumors

Publications (2)

Publication Number Publication Date
AU2010279678A1 AU2010279678A1 (en) 2012-03-01
AU2010279678B2 true AU2010279678B2 (en) 2015-09-10

Family

ID=43544613

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010279678A Active AU2010279678B2 (en) 2009-08-03 2010-08-02 Composition and methods of treating viral infections and viral induced tumors

Country Status (7)

Country Link
US (1) US20120164104A1 (https=)
EP (1) EP2462152A4 (https=)
JP (1) JP2013501056A (https=)
AU (1) AU2010279678B2 (https=)
BR (1) BR112012002551A2 (https=)
CA (1) CA2770282A1 (https=)
WO (1) WO2011017253A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
WO2009079481A2 (en) 2007-12-14 2009-06-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods to diagnose and immunize against the virus causing human merkel cell carcinoma
ES2572631T3 (es) 2008-01-25 2016-06-01 Chimerix, Inc. Métodos de tratamiento de infecciones virales
US20120034266A1 (en) * 2008-03-04 2012-02-09 Nel Andre E Methods and compositions for improving immune response by a nutraceutical antioxidant
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CA2779473C (en) * 2009-10-30 2016-08-16 Chimerix, Inc. Methods of treating viral associated diseases
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
WO2012031045A2 (en) * 2010-08-31 2012-03-08 Chimerix, Inc. Phosphonate ester derivatives and methods of synthesis thereof
US20140303092A1 (en) * 2011-10-26 2014-10-09 Chimerix, Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
EP3578563B1 (en) 2011-12-22 2021-04-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
SG10201800188SA (en) * 2013-03-15 2018-02-27 Univ California Acyclic nucleoside phosphonate diesters
US10221152B2 (en) * 2013-03-22 2019-03-05 Giant Force Technology Corporation Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus
US8962829B1 (en) 2013-11-15 2015-02-24 Chimerix, Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
CN111808136B (zh) 2014-09-15 2024-06-11 加利福尼亚大学董事会 核苷酸类似物
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
AU2017290703B2 (en) 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
WO2021035214A1 (en) 2019-08-22 2021-02-25 Emory University Nucleoside prodrugs and uses related thereto
CN113288896A (zh) * 2021-05-28 2021-08-24 成都中医药大学 槐定碱在制备抗疱疹病毒的药物中的用途
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
WO2024048657A1 (ja) * 2022-08-31 2024-03-07 シンバイオ製薬株式会社 リンパ腫の治療用医薬組成物
WO2024047811A1 (ja) * 2022-08-31 2024-03-07 シンバイオ製薬株式会社 リンパ腫の治療用医薬組成物
JP7827310B2 (ja) * 2022-08-31 2026-03-10 シンバイオ製薬株式会社 リンパ腫の治療用医薬組成物
WO2024219491A1 (ja) 2023-04-21 2024-10-24 シンバイオ製薬株式会社 神経膠腫の治療用医薬組成物
CN119080836B (zh) * 2024-11-07 2025-04-15 上海柯君医药科技有限公司 一种正痘病毒抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080009462A1 (en) * 2006-05-03 2008-01-10 Chimerix, Inc. Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates
WO2008133966A1 (en) * 2007-04-27 2008-11-06 Chimerix, Inc. Methods of reducing nephrotoxicity in subjects administered with nucleoside

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE1248654B (de) 1964-11-11 1967-08-31 Albright & Wilson (Mf g) Limited, Oldbury, Warwickshire (Großbritannien) Verfahren zur Herstellung von Phosphonsäuren und deren Salzen
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
US5047533A (en) 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
GB8530603D0 (en) 1985-12-12 1986-01-22 Leo Pharm Prod Ltd Chemical compounds
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5247085A (en) 1987-11-30 1993-09-21 Beecham Group P.L.C. Antiviral purine compounds
SU1548182A1 (ru) 1987-12-29 1990-03-07 Институт молекулярной биологии АН СССР 5 @ -Фосфонаты 3 @ -азидо-2 @ ,3 @ -дидезоксинуклеозидов, вл ющиес специфическими ингибиторами вируса СПИД в культуре лимфоцитов человека Н9/ШВ
IL91362A0 (en) 1989-08-20 1990-03-19 Yissum Res Dev Co Bisphosphonates,process for preparing them and pharmaceutical compositions containing them
US5196409A (en) 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
IT1241674B (it) 1989-10-12 1994-01-27 Boehringer Biochemia Srl Acidi gem-difosfonici, un processo per la loro preparazione e composizioni farmaceutiche che li contengono.
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
FI89365C (fi) 1990-12-20 1993-09-27 Leiras Oy Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
US5270365A (en) 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
JP3141053B2 (ja) 1991-12-26 2001-03-05 アベンティス ファーマ株式会社 ビスホスホン酸誘導体
FI945595A7 (fi) 1992-05-29 1994-11-28 Procter & Gamble Pharmaceuticals Inc Tiosubstituoituja typpipitoisia heterosyklisiä fosfonaattiyhdisteitä e pänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi
DE59309360D1 (de) 1992-12-02 1999-03-18 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5817647A (en) 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
US5656745A (en) 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
CA2171868A1 (en) 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
EP0753523A1 (en) 1995-07-10 1997-01-15 Gador S.A. Amino-substituted bisphosphonic acids
US5885973A (en) 1995-12-27 1999-03-23 Gador, S.A. Bone mass anabolic composition comprising olpadronate
US5717095A (en) 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
CA2195262C (en) 1996-01-18 2005-08-09 Masaru Ubasawa Phosphonate nucleotide compounds
US5877166A (en) 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5760013A (en) 1996-08-21 1998-06-02 National Science Council Thymidylate analogs and the use thereof
EP1012236A1 (en) * 1997-08-15 2000-06-28 Rubicon Laboratory Inc. Retrovirus and viral vectors
CA2385349A1 (en) 1999-09-24 2001-04-05 Francis J. Giles Method for the treatment or prevention of viral infection using nucleoside analogues
CA2747954C (en) 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
WO2008150438A1 (en) * 2007-06-01 2008-12-11 Luitpold Pharmaceuticals, Inc. Pmea lipid conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080009462A1 (en) * 2006-05-03 2008-01-10 Chimerix, Inc. Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates
WO2008133966A1 (en) * 2007-04-27 2008-11-06 Chimerix, Inc. Methods of reducing nephrotoxicity in subjects administered with nucleoside

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOSTETLER, K.Y. et al. "Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro" Molecular Cancer Therapeutics (2006) Vol.5 No.1 pages 156 to 159 *
RANDHAWA, P. et al. "Ether Lipid Ester Derivatives of Cidofovir Inhibit Polyomavirus BK Replication In Vitro" Antimicrobial Agents and Chemotherapy (2006) Vol.50 No.4 pages 1564 to 1566 *

Also Published As

Publication number Publication date
US20120164104A1 (en) 2012-06-28
WO2011017253A1 (en) 2011-02-10
AU2010279678A1 (en) 2012-03-01
JP2013501056A (ja) 2013-01-10
CA2770282A1 (en) 2011-02-10
EP2462152A4 (en) 2013-02-13
EP2462152A1 (en) 2012-06-13
BR112012002551A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
AU2010279678B2 (en) Composition and methods of treating viral infections and viral induced tumors
AU2010313273B2 (en) Methods of treating viral associated diseases
ES2915381T3 (es) Análogos de nucleótidos
US8163707B2 (en) 4′-allene-substituted nucleoside derivatives
AU2008246195B2 (en) Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates
Choi et al. A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl) methyl] guanine as a potent and selective anti-HBV agent
EP1406911B1 (en) 6-[2-(phosphonomethoxy)alkoxy] pyrimidine derivatives having antiviral activity
AU2002315625A1 (en) 6-2'-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity
AU2015264949A1 (en) Composition and methods of treating viral infections and viral induced tumors
AU2015203573A1 (en) Methods of treating viral associated diseases
Rygielska-Tokarska et al. Synthesis, antiviral, cytotoxic and cytostatic evaluation of N 1-(phosphonoalkyl) uracil derivatives
HK1240226A1 (en) Nucleotide analogs
HK1240226B (en) Nucleotide analogs
HK1063430B (en) 6-[2-(phosphonomethoxy)alkoxy]pyrimidine derivatives having antiviral activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 02 AUG 2019 TO 02 APR 2023 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 02 APR 2023

PC Assignment registered

Owner name: EMERGENT BIODEFENCE OPERATIONS LANSING LLC

Free format text: FORMER OWNER(S): CHIMERIX, INC.

HB Alteration of name in register

Owner name: EMERGENT BIODEFENSE OPERATIONS LANSING LLC

Free format text: FORMER NAME(S): EMERGENT BIODEFENCE OPERATIONS LANSING LLC